|
1
|
Ferlay J, Shin HR, Bray F, et al: GLOBOCAN
2008 v1.2, Cancer Incidence and Mortality wWorldwide: IARC
CancerBase No. 10 [Internet]. International Agency for Research on
Cancer; Lyon, France: 2010, http://globocan.iarc.fr.
Accessed October 1, 2013
|
|
2
|
Sorosky JI: Endometrial cancer. Obstet
Gynecol. 120:383–397. 2012.
|
|
3
|
Singh S, Raidoo S, Pettigrew G and
Debernardo R: Management of early stage, high-risk endometrial
carcinoma: preoperative and surgical considerations. Obstet Gynecol
Int. 2013:7572492013.
|
|
4
|
Albertini AF, Devouassoux-Shisheboran M
and Genestie C: Pathology of endometrioid carcinoma. Bull Cancer.
99:7–12. 2012.
|
|
5
|
Matias-Guiu X and Davidson B: Prognostic
biomarkers in endometrial and ovarian carcinoma. Virchows Arch.
464:315–331. 2014.
|
|
6
|
Yoo KH and Hennighausen L: EZH2
methyltransferase and H3K27 methylation in breast cancer. Int J
Biol Sci. 8:59–65. 2012.
|
|
7
|
Choi JH, Song YS, Yoon JS, et al: Enhancer
of zeste homolog 2 expression is associated with tumor cell
proliferation and metastasis in gastric cancer. APMIS. 118:196–202.
2010.
|
|
8
|
Fan T, Jiang S, Chung N, et al:
EZH2-dependent suppression of a cellular senescence phenotype in
melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer
Res. 9:418–429. 2011.
|
|
9
|
Lu C, Han HD, Mangala LS, et al:
Regulation of tumor angiogenesis by EZH2. Cancer Cell. 18:185–197.
2010.
|
|
10
|
Varambally S, Dhanasekaran SM, Zhou M, et
al: The polycomb group protein EZH2 is involved in progression of
prostate cancer. Nature. 419:624–629. 2002.
|
|
11
|
Kleer CG, Cao Q, Varambally S, et al: EZH2
is a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proc Natl Acad Sci USA.
100:11606–11611. 2003.
|
|
12
|
Weikert S, Christoph F, Köllermann J, et
al: Expression levels of the EZH2 polycomb transcriptional
repressor correlate with aggressiveness and invasive potential of
bladder carcinomas. Int J Mol Med. 16:349–353. 2005.
|
|
13
|
Bachmann IM, Halvorsen OJ, Collett K, et
al: EZH2 expression is associated with high proliferation rate and
aggressive tumor subgroups in cutaneous melanoma and cancers of the
endometrium, prostate, and breast. J Clin Oncol. 24:268–273.
2006.
|
|
14
|
Mannelqvist M, Stefansson IM, Wik E, et
al: Lipocalin 2 expression is associated with aggressive features
of endometrial cancer. BMC Cancer. 12:169–175. 2012.
|
|
15
|
Eskander RN, Ji T, Huynh B, et al:
Inhibition of enhancer of zeste homolog 2 (EZH2) expression is
associated with decreased tumor cell proliferation, migration, and
invasion in endometrial cancer cell lines. Int J Gynecol Cancer.
23:997–1005. 2013.
|
|
16
|
No authors listed. FIGO Committee for the
Ethical Aspects of Human Reproduction and Women’s Health Committee
Statement on Ethical Guidelines (Cairo, March 1998). J Obstet
Gynaecol. 19:444–447. 1999.
|
|
17
|
Trimble CL, Method M, Leitao M, et al:
Society of Gynecologic Oncology Clinical Practice Committee:
Management of endometrial precancers. Obstet Gynecol.
120:1160–1175. 2012.
|
|
18
|
Samarnthai N, Hall K and Yeh IT: Molecular
profiling of endometrial malignancies. Obstet Gynecol Int.
2010:1623632010.
|
|
19
|
Crea F, Fornaro L, Bocci G, et al: EZH2
inhibition: targeting the crossroad of tumor invasion and
angiogenesis. Cancer Metastasis Rev. 31:753–761. 2012.
|
|
20
|
Liang BJ, Li XP, Lu J, et al: Effects of
enhancer of zeste homolog (EZH2) downregulation on the
proliferation and invasion of nasopharyngeal carcinoma cell and the
possible mechanism. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.
47:298–304. 2012.(In Chinese).
|
|
21
|
Wang C, Liu X, Chen Z, et al: Polycomb
group protein EZH2-mediated E-cadherin repression promotes
metastasis of oral tongue squamous cell carcinoma. Mol Carcinog.
52:229–236. 2013.
|
|
22
|
Leng L, Huang Q, Dong Y, et al: EZH2 gene
silenced by siRNA suppresses the growth and invasion of endometrial
carcinoma cells. Nan Fang Yi Ke Da Xue Xue Bao. 33:866–869.
2013.(In Chinese).
|
|
23
|
Lin YW, Ren LL, Xiong H, et al: Role of
STAT3 and vitamin D receptor in EZH2-mediated invasion of human
colorectal cancer. J Pathol. 230:277–290. 2013.
|
|
24
|
Li H, Cai Q, Godwin AK and Zhang R:
Enhancer of zeste homolog 2 promotes the proliferation and invasion
of epithelial ovarian cancer cells. Mol Cancer Res. 8:1610–1618.
2010.
|
|
25
|
Zhou J, Roh JW, Bandyopadhyay S, et al:
Overexpression of enhancer of zeste homolog 2 (EZH2) and focal
adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol
Oncol. 128:344–348. 2013.
|
